BRCA1 and pure red-cell aplasia: The 2020 NCCN ‘Clinical Practice Guideline in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic; Version 1.2021′ state BRCA1/2 (and other cancer susceptibility genes) testing is clinically indicated in men (any age) with a personal history of metastatic or intraductal PrCa.